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Abstract
Backgound: No disease modifying treatment currently exists for Huntington’s disease (HD), a fatal
neurodegenerative disorder characterized by the formation of amyloid-like aggregates of the mutated huntingtin
protein. Curcumin is a naturally occurring polyphenolic compound with Congo red-like amyloid binding properties
and the ability to cross the blood brain barrier. CAG140 mice, a knock-in (KI) mouse model of HD, display abnormal
aggregates of mutant huntingtin and striatal transcriptional deficits, as well as early motor, cognitive and affective
abnormalities, many months prior to exhibiting spontaneous gait deficits, decreased striatal volume, and neuronal
loss. We have examined the ability of life-long dietary curcumin to improve the early pathological phenotype of
CAG140 mice.
Results: KI mice fed a curcumin-containing diet since conception showed decreased huntingtin aggregates and
increased striatal DARPP-32 and D1 receptor mRNAs, as well as an amelioration of rearing deficits. However, similar
to other antioxidants, curcumin impaired rotarod behavior in both WT and KI mice and climbing in WT mice.
These behavioral effects were also noted in WT C57Bl/6 J mice exposed to the same curcumin regime as adults.
However, neither locomotor function, behavioral despair, muscle strength or food utilization were affected by
curcumin in this latter study. The clinical significance of curcumin’s impairment of motor performance in mice
remains unclear because curcumin has an excellent blood chemistry and adverse event safety profile, even in the
elderly and in patients with Alzheimer’s disease.
Conclusion: Together with this clinical experience, the improvement in several transgene-dependent parameters
by curcumin in our study supports a net beneficial effect of dietary curcumin in HD.
Keywords: Huntingtin aggregates, Open field, Climbing, Pole task, Rotarod, Grip strength, Striatal mRNA transcripts,
Preclinical therapeutic trial
Background
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder caused by an elongated,
unstable, polyglutamine repeat near the N terminus of
the huntingtin gene [1]. Recent studies have shown that
many symptoms including behavioral, cognitive and
motor changes are present in gene carriers decades
prior to the clinical onset of the disease [2,3]. Further,
pathological changes including striatal atrophy, cortical
thinning and white matter loss, aggregates of mutant
huntingtin, receptor loss and microgliosis are present
many years prior to predicted age of disease onset
[4-10]. Therefore neuroprotective treatments may need
to be started in gene carriers long before the onset of
manifest disease [7]. This requires the use of drugs with
an excellent safety profile over long periods of
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any medium, provided the original work is properly cited.administration. Moreover, it is possible that this early
drug treatment could prevent later downstream toxicity
due to the huntingtin protein.
CAG140 knock-in (KI) mice a r eas l o w l yp r o g r e s s i n g
mouse model of HD that exhibit pathological, molecular
and behavioral deficits as early as 2 years before devel-
oping spontaneous motor deficits which is itself reminis-
cent of the clinically manifest phase of HD [11,12].
These mice express a chimeric human/mouse Hdh pro-
tein, including human mutant exon1 with approximately
140 CAG repeats. When they begin to show obvious
anomalies in homecage behavior around 2 years of age,
these mice show 38% loss in striatal volume and 40%
striatal neuronal loss, remarkably similar to the 1/3 to
1 / 2l o s si nH Dp a t i e n t sa tp h e n o - c o n v e r s i o n[ 4 ] .I n
CAG140 mice, this is preceded by stride deficits, neuro-
chemical anomalies, cortical gliosis and cortical and
striatal electrophysiological changes at 12 months of age
[11-14]. However, deficits in open field, climbing, sen-
sorimotor activity, wheel running, motor learning, and
anxiety, as well as pathological accumulation and aggre-
gation of huntingtin in the nucleus and cytoplasm are
typically present prior to 6 months of age, with some
anomalies occurring as early as 1 month of age [11,12].
In addition, reduced actin polymerization, abnormal
long term potentiation, and deficits in long-term novel
object recognition memory are present by 4 months in
these mice [15]. Thus, the CAG 140 KI mice provide an
excellent opportunity to study and treat the earliest
changes induced by the mutant protein.
Curcumin, a major bioactive component of turmeric,
has multiple pharmacological properties and has shown
beneficial effects in in vivo models of aging, ischemia
and trauma [16-19]. In addition to its anti-inflammatory
and antioxidant activities, curcumin is a Congo red-like
agent with anti-aggregate properties, and it can cross
into brain parenchyma as shown by measurement in
brain tissue following administration in the diet [20-22].
Its anti-amyloid properties and oral availability suggest
that it may be a promising compound for the treatment
of several neurodegenerative diseases. Indeed, in mouse
models of Alzheimer’s disease, curcumin and related
curcuminoids reduced plaque burden and microglia,
improved cognitive function, and protected against Ab
toxicity in vitro and in vivo [20,23-26]. Further, its low
toxicity demonstrated by millennia of use as a food
additive makes curcumin an attractive possibility for the
early and chronic treatment of neurodegenerative
diseases.
Here, we tested the hypothesis that the Congo-red-
like properties of curcumin could be exploited to
reduce the early neuropathology in CAG140 KI mice,
without the toxicity and need for intracerebral delivery
associated with Congo red administration [27]. To
determine whether any effect on pathology was ulti-
mately beneficial for cellular function, we measured a
panel of striatal transcripts known to be altered by
transcriptional dysregulation resulting from mutated
huntingtin expression [28]. Although our in vitro stu-
dies here show that dosing is important, as others have
shown [20,29], safety and toxicity studies in vivo have
repeatedly shown that curcumin has a very favorable
safety profile [30,31]. Curcumin is an anti-oxidant and
induces antioxidant response elements [29,32].
Although oxidative damage can mediate pathogenesis
in neurodegenerative diseases, redox balance is impor-
tant for several aspects of physiology including learn-
ing and memory, and normal cellular function [33].
Therefore, we conducted a study of motor behavior in
WT and KI mice treated from conception as well as a
study in WT mice treated as adults.
Results
W T ,K Ia n dH E Tm i c ew e r ea d m i n i s t e r e dc u r c u m i n
via chow at a continuous dose of 555 ppm. HET mice
were not behaviorally tested, but were perfused with
PBS at the end of treatment (identical, parallel treat-
ment with WT and KI mice) for curcumin measure-
ment in blood-free brain tissue. As expected from
previous studies with the same regimen in mouse
models of Alzheimer’s disease, curcumin levels in
b r a i nt i s s u ew e r ei nt h en a n o m o l a rr a n g e( T a b l e1 ) .
No curcumin was detected in control-treated mice
(Table 1). Curcumin levels were slightly elevated in
fresh frozen tissue, reflecting blood content (Table 1).
Thus, this regimen provided therapeutic levels of cur-
c u m i ni nb r a i nt i s s u eb a s e do ne v i d e n c et h a tav e r y
similar curcumin regimen was beneficial in mouse
models of Alzheimer’s disease [20,25,26]. A dose of
555 ppm (555 mg/kg food; 92 mg/kg mouse body
weight; calculations based on [20]) correlates to a dose
of approximately 7.1 mg/kg human body weight or 625
mg curcumin per day based on the recommended cor-
relation to body surface area (http://www.accessdata.
fda.gov/scripts/cder/onctools/animalquery.cfm and
[34]; using a weight of 87 kg [US male average] and
height of 177.6 cm [US male average] and mouse
weight of 30 g). Although no study to date has mea-
sured curcumin levels in the brain of patients treated
with curcumin, the dose used in this study is well
Table 1 Curcumin levels in whole brain from curcumin-
treated mice
Treatment Fresh frozen (nM) PBS-perfused (nM)
Curcumin 174 ± 17 128 ± 8*
No curcumin was detected in control-treated tissue (n = 2 WT fresh frozen, n
= 4 HET PBS-perfused). Data are mean ± sem. Group sizes are 3 (WT, fresh
frozen) and 5 (HET, PBS-perfused). *p < 0.05 compared to fresh frozen.
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patients without adverse effects on blood chemistries
or other serious adverse side effects [30,35].
Curcumin is a non-flavonoid polyphenolic and as both
flavonoids and non-flavonoids can cross the placenta
[36,37] it was administered from conception. In agree-
ment with previous studies [38,39] we found no differ-
ence in either the number of pups born or number of
pups weaned between control-fed and curcumin-fed
dams (Table 2, effect of food, F(1,18) = 0.39, ns, interac-
tion between food and age of pups (birth to weaning), F
(1,18) = 1.59, ns). In addition, there was no difference
between groups in the percentage of pups brought
through to weaning per dam (Table 2, Student’s t test,
ns). Thus, as expected, we found no deleterious effects
of dietary curcumin on fecundity.
We have previously shown that CAG140 KI mice
show normal body weight gain up to 7 m of age, with
reduced body weight noted from 1 y of age [40].
Because our goal was to examine the effects of curcu-
min on the earliest manifestations of mutant hunting-
tin, mice were euthanized at 4.5 m. At this age
CAG140 KI mice typically show robust neuropatholo-
gical changes and behavioral deficits, however overt
spontaneous changes do not occur until 2 years of age
[11,12]. Weight was monitored in WT, KI and Het
mice. In keeping with known toxicological data on cur-
cumin, male body weight was normal and was unaf-
fected by curcumin (males, genotype × food × age F
(34,812) = 0.63, ns). There was an overall effect of gen-
otype in female mice although post hoc testing showed
no between-groups differences at any age (effect of
genotype F(2,62) = 4.71, p < 0.02), and again there was
no effect of food (F(1,62) = 2.2, ns) or interaction
between food, genotype and age (genotype × food ×
a g eF ( 3 4 , 9 1 3 )=0 . 7 ,n s ) .T h e r e f o r e ,c u r c u m i nd i dn o t
appear to have any deleterious effects on general
h e a l t h( F i g u r e1 ;o n l yW Ta n dK Id a t aa r es h o w n ) .W e
did not measure food utilization in this group of mice,
however in a subsequent trial of similar length, con-
ducted in normal adult C57Bl/6 J mice, food utilization
was similar between groups, indicating that palatability
did not differ between treated and untreated chow (3-4
g eaten per mouse per day; Figure 2, food × age inter-
action, males: F(42, 168) = 1.43, ns; females: F(42,168)
=0 . 6 9 ,n s ) .
In vitro and in vivo neuropathological analysis
A primary goal of the experiment was to determine
whether curcumin, which has anti-amlyoid properties,
could affect protein aggregates of huntingtin in the stria-
tum of CAG140 KI mice. High concentrations of curcu-
min increases aggregate size in vitro [41] and indeed,
using PC12 cells that inducibly express EGFP-tagged
exon 1 of mutant htt [42], we found that 10 or 20 μM
curcumin, applied at the same time as protein induction,
increased aggregate size markedly at 48 or 72 h post
mutant-protein induction (Figure 3; 48 h, Kruskal-Wallis
ANOVA p < 0.01, *p < 0.05 compared to control treated
cells; 72 h, Kruskal-Wallis ANOVA p < 0.01, *p < 0.05
compared to control treated cells). In contrast to 20 μM
curcumin, 5 nM curcumin caused a slight reduction in
aggregate size at 48 h (Figure 3; 48 h, Kruskal-Wallis
ANOVA as above, *p < 0.05 compared to control trea-
ted cells) but the effect was very small (-8% reduction in
size of all aggregates) and was only observed with the
lowest concentration tested, which is well below the
concentration of curcumin measured in brain in our
study (Table 1).
Despite the lack of clear effects of low concentrations
of curcumin in vitro on aggregate sizes, we observed a
clear decrease in aggregate numbers in the striatum of
KI mice after administration of curcumin in vivo.O n l y
tissue from KI mice was examined because huntingtin-
stained nuclei and aggregates are not detected in the
brain of WT mice [12]. An histological approach to ana-
lyzing aggregates was chosen to allow for the separate
analysis of several types of aggregates; in addition, we
performed a regional analysis by examining two levels of
striatum, and the level of striatum was included as a fac-
tor in the ANOVA analyses because it had a significant
effect on the distribution of neuropil aggregates (F(1,20)
= 9.74, p < 0.01), diffusely stained nuclei (F(1,20) =
25.37, p < 0.0001) and microaggregates (F(1,20) = 29.76,
p < 0.0001), independent of treatment. Importantly,
power calculations show that a group size of 2-3 mice
are sufficient to detect a 30% change in the number of
stained nuclei, or number of nuclei containing microag-
gregates (a = 0.05, 80% power), thus, our group sizes
were well powered to detect treatment effects.
At 4.5 m of age, curcumin-fed KI mice had less diffu-
sely stained nuclei, the earliest huntingtin-related
pathology observed in mutant mice, than control-fed
Table 2 Reproductive success of heterozygous CAG140 dams treated with curcumin
Treatment Pups/dam born Pups/dam weaned Percent of pups brought through to
weaning
Control 6.3 ± 0.45 5.8 ± 0.7 94 ± 12
Curcumin 6.6 ± 0.43 4.7 ± 0.9 81.1 ± 16
Data are mean ± sem.
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Page 3 of 16Figure 1 Body weight profiles of WT and KI mice fed curcumin or control chow. No difference was detected between curcumin-fed and
control-fed male mice, and while an overall effect of genotype was detected in female mice, no effect of food, or interaction of food and
genotype, or food and genotype and age were found in either gender, indicating, as expected, no deleterious effect of curcumin. Data shown
are mean ± sem. WT male n = 13-15; WT female n = 15-19; KI male n = 7-10; KI female n = 7-9. Data analyzed using GLM ANOVA followed by
post hoc Bonferroni t-tests.
Figure 2 Chow utilized by control-fed and curcumin-fed adult C57Bl/6 J mice. No difference was noted between the groups. Data are
mean ± sem. N = 9-10 per group.
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4A, B, C). Curcumin-treated KI mice also showed fewer
microaggregates, defined as numerous, small, nuclear
puncta, similar to those previously observed in other
models of HD [44-46] (effect of treatment F(1,20) =
12.73, p < 0.01; Figure 4A, B, C). Nuclear inclusions
were reduced by curcumin but this effect did not reach
significance (effect of treatment F(1,20) = 4.3, p =
0.052). By far the largest reduction observed in curcu-
min-treated mice (-17% in lateral sections, -45% in med-
ial sections) was on neuropil (cytoplasmic) aggregates in
the striatum (effect of treatment, F(1,20) = 5.22, p <
0.05, Figure 4A, B, C). These data indicate that curcu-
min improved a key pathological consequence of the
HD-causing mutation in vivo.
Transcriptional changes
Having established a profound effect on htt aggregation,
we went on to assess whether transcription was also
improved. Together with the formation of protein aggre-
gates, transcriptional dysregulation is a major effect of
mutant huntingtin [48]. We have previously detected
profound changes in striatal transcripts for enkephalin
but not substance P at 4 months of age in a similar line
of KI mice with 94 CAG repeats (CAG94; [28]). We
have also detected a significant decrease of D1, D2
dopamine and CB1 receptors, enkephalin and DARPP-
32, but not substance P mRNA at 4 months of age in
CAG140 KI mice [49]. Power calculations showed that
group sizes of 2-7 (depending on transcript) are
required to detect a 50% change in the number
transcripts in the KI mice (a = 0.05, 80% power), thus
our group sizes were well powered to detect treatment
effects (n = 7 for each KI group). The housekeeping
gene used was HPRT, as used previously [50-52]. In a
separate group of mice (n = 23), we found that HPRT
showed excellent correlation to results obtained using
other housekeeping genes, with r
2 =0 . 8 6 2a n ds l o p eo f
1.08 (Figure 5, p < 0.0001 [53]).
We confirmed striatal transcriptional dysregulation in
the control-fed KI mice compared to WTs (Table 3,
effect of genotype: Enkephalin F(1,26) = 78.1, p <
0.0001; D1 F(1,26) = 27.5, p < 0.0001; D2 F(1,26) = 29.6,
p < 0.0001; DARPP-32 F(1,26) = 51.7, p < 0.0001; CB1 F
(1,26) = 21.8, p < 0.0001; and post hoc tests using Bon-
ferroni’s multiple t-tests, corrected for 4 comparisons).
Curcumin treatment attenuated several deficits in KI
mice, with D1 and CB1 mRNA no longer being different
to control-fed WT mice, and the levels of DARPP-32
and D1 receptor mRNA being significantly increased
compared to control-fed KIs (Table 3). No transcripts
were significantly affected in WT mice (Table 3).
Behavioral analysis
In addition to curcumin’s effect on pathological and
molecular changes induced by mutant huntingtin we
also examined the effects of curcumin on the early
behavioral deficits in KI mice. Analyses were carried out
at 1 month (open field), 1.5 month (climbing) and 4
months of age (pole task and rotarod). Several beha-
vioral deficits are typically present in these tests at these
ages in the KI mice, indicative of the extensive neural
dysfunction present at these early ages [11,12,49].
For mice treated with curcumin or control diets from
conception, there was no effect of gender on any of the
tasks examined (effect of sex: for open field first 5 mins
F(1,85) = 3.6, ns; climbing: F(1,80) = 3.1, ns; pole task: F
(1,77) = 0.003, ns; rotarod 10 rpm: F(1,81) = 2.8, ns, 20
rpm, F(1,81) = 0.21, 30 rpm F(1,81) = 0.92, ns; no inter-
action between genotype, treatment and sex: for open
field: first 5 mins, F(1,85) = 2.1, ns); climbing: (F(1,80) =
1.4, ns); pole task: (F(1,77) = 2.6, ns) or rotarod (10
rpm: F(1,81) = 0.03, ns; 20 rpm: F(1,81) = 0.38, ns; 30
rpm, F(1,81) = 0.6, ns). Therefore, data from males and
females were grouped for analysis.
Curcumin treatment rescued the reduced rearing in KI
mice observed in the first five min in the open field
(genotype × treatment F(1,89) = 4.36, p < 0.05, Figure
6). As previously shown [11], climbing was decreased at
1 . 5m o n t h si nK Im i c e( T a b l e4 ,e f f e c to fg e n o t y p eF
(1,84) = 4.6, p < 0.05; no overall interaction between
genotype and treatment F(1,84) = 3.1, ns). Post hoc ana-
lysis showed that compared to control diet curcumin
abrogated the difference between KI and WT curcumin-
fed mice suggesting a beneficial effect of treatment.
Figure 3 At nanomolar concentrations, curcumin slightly
reduces aggregate size and at micromolar concentrations,
curcumin increases aggregate size in PC12 cells inducibly
expressing exon 1 of mutant htt [42]. Cells were induced with 0.1
μM tebufenozide and treated with curcumin (5 nM, 50 nM, 500 nM,
5 μM, 10 μMo r2 0μM) or vehicle (DMSO) at the same time.
Uninduced cells (treated with EtOH (vehicle) were used as a control
for expression of the mutant protein) are not shown. At 48 h, cells
treated with 5 nM curcumin show an 8% reduction in size of
aggregates compared to vehicle-treated induced cells (no
curcumin). At 48 h and at 72 h, 10 or 20 μM increase aggregate size
markedly, possibly reflecting curcumin’s effect on the UPS at
micromolar concentrations [43]. Data shown are of the mean ± sem
of n = 4 independent experiments.
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Table 4). This suggests that the effect of curcumin on
HD pathogenesis may be stronger than, and opposite to,
the “off-target” effects in WT mice.
As previously shown [11], 4 month old control-fed KIs
were impaired on the pole task (Table 4, effect of geno-
type F(1,81) = 10.1, p < 0.01). Curcumin-treated KIs
were no longer significantly different from WT controls,
indicating a small beneficial effect (Table 4). In agree-
ment with other studies of rotarod performance of
knock-in mice [55], we have previously shown that
impairments on the rotarod in CAG140 KI mice are
very subtle, with no impairments during accelerating
protocols and small impairments during fixed speed
protocols [11]. In the present study, control-treated KIs
showed no defects in rotorod peformance, and actually
performed slightly better than WTs on training days 3
and 4. However, curcumin impaired performance in
b o t hW T sa n dK I st h r o u g h o u tt r a i n i n g .T h ec u r c u m i n -
treated mice appeared to learn the task during training,
since all mice improved over successive days, having
started out with similar performances (see Figure 7, day
1). However, over time, both control-fed WTs and con-
trol-fed KIs showed improved performance above that
of their genotype matched curcumin-fed counterparts
(Figure 7, training: days 1 through 4, accelerating para-
digm, smooth axle, effect of treatment F(1,86) = 9.2, p <
0.01, no interaction of genotype and treatment F(1,86) =
Figure 4 Curcumin reduces aggregates in KI mice. Mice were fed curcumin from conception and were analyzed for huntingtin aggregates,
at 4.5 m of age. The mean number of stained nuclei (data not shown), stained nuclei containing microaggregates or inclusions, and neuropil
aggregates per 20 μm
2 were counted over the entire striatum of each of two sections per mouse (1.32 mm and 2.28 mm lateral of the midline
[47], data from medial section shown). A) control-treated KI mouse, B) curcumin-treated KI mouse. Arrowheads indicate stained nuclei containing
inclusions. Small line arrows indicate neuropil aggregates and arrows indicate stained nuclei with microaggregates. C) Quantification of
neuropathological analysis. Curcumin reduces several forms of aggregated huntingtin in 4.5 m old KI mice, data from medial section shown.
Although the reduction in number of inclusions is not significant, a strong trend towards reduction was observed (effect of treatment F(1,20) =
4.3, p = 0.052). Data are shown as mean ± sem and were analyzed using ANOVA followed by Fishers LSD post hoc tests. N = 6 per group. * p <
0.05, **p < 0.01, compared to control-treated KI. Arrows are as for A) and B). Scale bar = 20 μm for A) and B).
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training phase, on day 5 with the smooth axle fixed
speed paradigm (effect of treatment F(1,85) = 12.6, p <
0.001; for example at 20 rpm: WT control 139 ± 39 s,
W Tc u r c u m i n3 7±7 ,K Ic o n t r o l ,1 8 2±6 4 ,K Ic u r c u -
min 34 ± 9, WT control versus WT curcumin p < 0.01,
KI control versus KI curcumin p < 0.01, Fishers LSD
post hoc, no interaction of genotype and treatment F
(1,85) = 0.5, ns), and on day 6 with the grooved axle
(effect of treatment F(1,85) = 16.3, p < 0.001; for exam-
ple 30 rpm WT control 274 ± 47 s, WT curcumin 81 ±
26, KI control, 248 ± 68, KI curcumin 91 ± 40, WT
control versus WT curcumin p < 0.01, KI control versus
KI curcumin p < 0.01, Fishers LSD post hoc; no interac-
tion of genotype and treatment F(1,85) = 0.6, ns; 1 WT
control mouse died before days 5 and 6).
To determine whether the deleterious effects of curcu-
min in WT mice on climbing and rotarod performance
were related to exposure to curcumin during early
development, we conducted a separate trial of curcumin
Figure 5 Correlation and linear regression analysis of levels of
striatal DARPP-32 mRNA. Using a separate group of mice to those
used in our curcumin preclinical trial (n = 23 in total), we correlated
levels of DARPP-32 mRNA normalized using HPRT or Atp5b and
Eif4a [53]. We found excellent correlation between the results
obtained with HPRT and with Atp5b and Eif4a (r
2 = 0.862 and slope
of 1.08, p < 0.0001).
Table 3 Effect of curcumin treatment on striatal transcripts
Transcript Control-treated Curcumin-treated Treatment effect in KIs
WT KI Percent change
from WT
WT KI Percent change
from WT
Percent rescue from control-
treated KI levels
D1 receptor 1.13 ± 0.13 0.64 ± 0.04* -43.4 1.1 ± 0.04 0.8 ± 0.03
‡ -27.4 +25
D2 receptor 1.31 ± 0.12 0.73 ± 0.04** -44.1 1.07 ± 0.05 0.84 ± 0.04* -22.1 +14
CB1
receptor
0.93 ± 0.13 0.48 ± 0.07* -48.5 1.03 ± 0.09 0.61 ± 0.05 -40.9 +26.7
DARPP-32 1.28 ± 0.1 0.61 ± 0.03** -52.1 1.09 ± 0.06 0.79 ± 0.04**
‡ -27.4 +29.5
Enkephalin 1.06 ± 0.06 0.55 ± 0.04** -47.7 0.98 ± 0.06 0.56 ± 0.04** -43.0 +1.5
Substance
P
0.95 ± 0.06 0.99 ± 0.07 +5.1 0.91 ± 0.09 0.95 ± 0.09 +4.7 -4.2
WT n = 8 per group, KI n = 7 per group. * p < 0.05, ** p < 0.01 compared to control-treated WT (comparisons to WT curcumin not shown, for clarity).
‡ p < 0.05
compared to control-treated KI. Raw data were compared using completely randomized ANOVA followed by Bonferroni’s corrected for 4 comparisons. Groups
were composed of balanced mixed-gender groups. Data were processed as described previously [54].
Figure 6 Curcumin rescues rearing deficit in KI mice. Control KI
mice rear less than their littermate WT controls and treatment with
curcumin abolished this deficit. Data are mean ± sem of first 5 min
in open field. ** p < 0.01 compared to control-fed WTs, ΔΔ p < 0.01
compared to control-fed KI group. Groups were composed of
balanced mixed gender groups since there was no significant effect
of gender (see text). Data were analyzed using ANOVA followed by
Fishers LSD post hoc tests. WT n = 29-32, KI n = 16 per group.
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months and continued until 8 months of age, to match
the total length (gestation and postnatal) of treatment
used in the CAG140 trial (approximately 23 weeks).
As in the life-long curcumin trial, both male and
female curcumin-fed WT mice were impaired in rotarod
performance by endpoint (Figure 8A, 8 months, treat-
ment × training session F(2,70) = 4.1, p < 0.03). We did
not observe curcumin-induced impairments in climbing
until 8 months of age. This deficit was only in males,
however, climbing activity was reduced in all females at
this age, possibly obscuring any treatment effects (Figure
8B, gender × treatment interaction at 8 months, F(1,35)
= 6.2, p < 0.02). The reduction in rotarod performance
was not due to a general effect of curcumin on move-
ment, since there was no effect of curcumin on distance
moved in the open field (Figure 8C, effect of day F
(3,105) = 36.7, p < 0.0001, treatment × day interaction F
(3,105) = 0.93, ns). Grip strength was actually increased
by curcumin treatment and then normalized by the end-
point (Figure 8D). As expected, gender impacted muscle
strength, thus, the analysis was conducted separately in
males and females (Figure 8D, treatment × gender ×
time, F(2,70) = 4.3, p < 0.02). These data demonstrate
that muscle strength was not impaired in curcumin-
treated mice, and as such does not explain the impaired
rotarod performance. Latency to immobility was
unchanged between treatment groups in the forced
swim task indicating that behavioral despair, also, was
not the cause of the impaired rotarod performance (data
were analyzed separately in males and females since
gender impacted levels of immobility, latency to immo-
bility: treatment × gender F(1,35) = 0.26, ns; data not
shown).
Taken together, these data in adult WT mice demon-
strated that fine motor coordination, muscle strength,
depressive behavior and activity levels were not the
cause of impaired rotarod or climbing performance
induced by curcumin treatment. Nevertheless these
deleterious effects are not unexpected, since CoQ10 is
an anti-oxidant and component of the electron transport
chain, also impairs rotarod performance in WT mice
[56,57].
Discussion
Curcumin, a component of turmeric, has beneficial
effects in animal models of several types of neurodegen-
erative diseases [16-20,23-26]. Indeed, clinical trials with
curcumin are underway for mild cognitive impairment
and Alzheimer’s disease http://www.clinicaltrials.gov.
Curcumin has many reported properties including dose
dependent effects on protein aggregation and transcrip-
tion, as well as anti-inflammatory and anti-oxidant
effects [20,31]. Importantly, curcumin is safe in clinical
tolerability trials even in elderly AD patients [30,35]. It
labels amyloid plaques in the brain of mouse models of
AD in vivo and ex vivo following i.p. or oral administra-
tion [24,26] and fibrillar intracellular tau in human AD
pathological samples [58]. Curcumin is capable of inhi-
biting aggregation and disaggregating Ab in vitro and
this depends on the fibril-related conformation rather
Table 4 Effect of curcumin treatment on climbing
behavior and pole task performance in CAG140 KI and
WT mice
Number of climbs (1.5
m)
Time taken to turn (4
m, (s))
WT KI WT KI
Control-treated 1.21 ± 0.33 0.14 ± 0.1** 3.01 ± 0.35 5.22 ± 0.84**
Curcumin-
treated
0.48 ± 0.17* 0.38 ± 0.18* 3.03 ± 0.32 4.06 ± 0.69
WT n = 26-30, KI n = 14-16, * p < 0.05, ** p < 0.01 compared to control-
treated WT (comparisons to WT curcumin not shown, for clarity). Groups were
composed of balanced mixed gender groups as there was no significant
effect of gender (see text).
Figure 7 Although at this age no rotorod deficits were detected in the KI mice relative to WT, curcumin lowered performance scores.
At the end of the trial, when tested on the rotarod, both WT (left) and KI (right) mice treated with curcumin showed impaired performance.
Data shown are mean ± sem. Groups were composed of balanced mixed gender groups since there was no significant effect of gender (see
text). Data were analyzed using ANOVA followed by Fishers LSD post hoc tests. WT n = 28-30, KI n = 15-16 per group. *p < 0.05, ** p < 0.01
compared to genotype-matched controls on the same day.
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min indicate its potential for HD.
We treated WT and CAG140 KI mice, a genetically
accurate model of HD, with 555 ppm curcumin in their
chow from conception in order to expose the mice to
the agent for as long as possible. We chose this dose
because higher doses may actually be less beneficial due
to the demonstrated toxic effects of micromolar levels
of curcumin in an in vitro model of HD [41] and lesser
efficacy in reducing amyloid burden in the Tg2576
mouse [25]. At micromolar concentrations, curcumin
inhibits the proteasome, which may exacerbate the dis-
ease, and increased aggregate sizes in vitro in our study.
Therefore, we chose a low concentration that has been
previously shown to produce beneficial effects in mouse
models of AD [20,25,26]. This dose is much lower than
doses previously shown to be safe in a 6 months treat-
ment in elderly patients [35].
Free (unglucuronidated) curcumin can cross the blood-
brain barrier following oral administration [20,21,26,59]
and is detected in blood-free mouse brain parenchyma
following oral and systemic administration at one hour
after last dose in an acute dosing (1 gavage per day, for 2
days) regimen [20]. After initial loading, curcumin is very
stable in lipid environments, and after chronic dosing
produces constant levels in the blood [20]. Plasma levels
in Tg2576 after several months dosing were near 100 nM
[20]. In agreement with these previous studies [20] we
detected nanomolar levels of curcumin in the brain. We
found that curcumin in vivo decreased several forms of
mutant huntingtin aggregates visible with light micro-
scopy in brain tissue. Curcumin can also inhibit the for-
mation of fibrils of Abeta40 in vitro [26] and
furthermore, it has been shown to cross cell membranes,
and enter nuclei [60,61]. Thus, it is possible that it
directly inhibited or slowed aggregate formation, result-
ing in the reduced density observed after in vivo curcu-
min treatment. However, our attempt to demonstrate a
direct effect of curcumin on aggregate sizes in PC12 cells
inducibly expressing exon 1 of mutant htt only revealed a
minimal effect at low concentrations, while confirming
an increase in aggregate size at μM concentrations.
Although the rapid formation of aggregates in vitro
clearly differs from the slow process occurring in vivo in
brain, our data do not demonstrate conclusively that the
effect of curcumin on aggregates is direct.
Figure 8 Curcumin impairs rotarod performance in normal C57Bl/6 J mice, but does not affect forelimb muscle strength, or locomoter
activity. Adult mice were fed from 2.7 m until 8 m of age with curcumin, to approximate the duration that CAG140 mice were fed (gestation +
neonatal + adult). Curcumin impaired performance in the rotorod in a gender-independent manner (A). At 8 m age curcumin treatment of
males by not females was associated with climbing deficits. Overall, females climbed less than males possibly obscuring treatment effects (B).
Curcumin improved grip strength at 4.5 m age, but did not affect grip at other ages tested (C). D) Activity in the open field was normal. Data
are shown as mean ± sem, n = 10 per group (n = 9 in curcumin-fed females). Data were analyzed using ANOVA followed by Fishers LSD post
hoc tests. *p < 0.05, **p < 0.01 compared to control-fed gender-matched mice.
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aggregate, large inclusion bodies, are protective [62,63].
However, recent data suggest that reducing improper
folding of monomeric htt may reduce both inclusion
bodies and cell death [64]. Additionally, the speed of
aggregate formation may predict their toxicity [65,66].
Thus, it is possible that reducing or preventing even the
large “protective” aggregates, could be beneficial to the
cell. To determine whether the effects of curcumin on
aggregates have beneficial consequences for cellular
functions, we also measured several striatal transcripts
that are known to be affected by mutant huntingtin and
which are markedly decreased in the striatum of control
CAG 140 KI mice. In favor of a beneficial effect of cur-
cumin on huntingtin pathology, several deficits in stria-
tal transcripts in curcumin-fed KI mice were attenuated
in this study. CB1 and D1 levels in curcumin-treated
KIs were no longer different to control WTs, and
furthermore, the transcripts encoding DARPP-32 and
D1 receptors were significantly improved from control-
fed KIs. Previously, we have demonstrated, using optical
density, that DARPP-32 levels are normal at 4 m of age
i nt h e s em i c e[ 1 1 ] .T h e r e f o r e ,w ed i dn o tm e a s u r et h e
effects of curcumin on this protein. It is not unusual for
mRNA levels to decrease prior to protein levels [67] and
i n d e e d ,b y1 2m ,w eh a v ef o u n dap r o f o u n dl o s so f
DARPP-32 protein (by optical density) in these mice
[11]. In general, it appears that the mRNA levels are a
more sensitive measure of neuronal dysfunction than
protein levels at early stages of the disease in this slowly
progressive mouse model.
In addition to protective effects of curcumin on
pathology and transcription, lifelong treatment rescued
deficits in rearing in the open field observed in these
mice at 1 month of age and differences in climbing and
the pole test normally observed between KI and WT
mice were abolished by curcumin. The effects of treat-
ment on behavioral deficits were more modest at 4.5
months, suggesting that most of the beneficial effect of
curcumin may occur prior to or during the period of
aggregate formation [12]. Some of the behavioral
improvements observed at 4.5 months may be related to
improvements in the level of the striatal transcripts for
the D1 dopaminergic receptor and DARRP-32 as these
molecules play a key functional role in subsets of striatal
efferent neurons [68]. However, the modest improve-
ment in other transcripts may explain the limited beha-
vioral benefits observed. For example, decreases in CB1
mRNA in HD have recently been shown to be particu-
larly critical for functional outcome [69].
Curcumin treatment had detrimental effects on some
motor behaviors both in WT and KI mice. Specifically,
climbing was affected by curcumin in WTs and rotarod
performance in both genotypes. This effect was not due
to the administration of curcumin during pre or early
post-natal development because even when administered
in adulthood for a similar length in time, curcumin
impaired rotarod performance in 8 month old WT
C57Bl/6 J mice of both sexes, and also impaired climb-
ing in males. The detrimental effect of curcumin on
motor behavior was not due to an effect on body weight
since curcumin-treated mice had similar body weight to
control-fed mice. Similarly, it is unlikely that this effect
is related to a general muscle weakness because curcu-
min-treated adult WT mice initially showed increased
grip strength, which then normalized. Activity and food
utilization were unaffected by curcumin treatment, and
we found no evidence of behavioral despair in the
forced swim test. Intriguingly, previous studies have
shown that the anti-oxidant CoQ impairs rotarod per-
formance in WT mice [57], which we have also noted in
WT littermates of CAG140 mice [56]. Other antioxi-
d a n t sl i k eE G C Gh a v eb e e ns h o w nt oi n t e r f e r ew i t h
climbing behavior by impacting the dopaminergic trans-
mission [70]. Detrimental effects of anti-oxidants on
mouse motor behavior could be related to their effects
on redox balance which is important for several aspects
of physiology including learning and memory, and nor-
mal cellular function and in particular autophagy, a
c l e a r a n c em e c h a n i s mt h a tm a yp l a yak e yr o l ei nH D
pathophysiology [71]. This latter mechanism, however,
is difficult to reconcile with our observation that curcu-
min treatment reduces htt aggregates in striatum. The
significance of these adverse behavioral effects of both
CoQ and curcumin for the potential therapeutic use of
these compounds remains unclear. Indeed, CoQ has
been used for many years in patients with Parkinson’s
disease and in clinical trials of HD for many years with-
out adverse effects [72,73]. Furthermore, blood chemis-
tries and the absence of significant adverse effects
showed that curcumin was safe and well-tolerated in
recent trials in AD and in the elderly [30,31,35]. There-
fore, the detrimental effects observed in mice with these
compounds are unlikely to be of clinical significance.
Interestingly, curcumin tended to reduce transcripts in
WT mice, but this did not reach significance. Most of
the deleterious effects were in WT mice and they
tended to be in the opposite direction to the effect on
KIs, which may indicate that the agent affects WT phy-
siology differently to the mutant physiology.
Conclusions
In summary, in this first report of curcumin as a thera-
peutic in vivo for HD, we have found that curcumin
ameliorated three aspects of HD in CAG140 KI mice,
with the most notable effect on the htt aggregates. We
also observed partial improvement of transcriptional
deficits, and partial behavioral improvement. Despite the
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ment in both KI and WT mice of unknown significance
for humans, further investigation of this compound for
its use in HD is warranted.
Methods and materials
In vitro aggregate experiments
PC12 cells inducibly expressing EGFP-tagged exon 1 of
mutant htt were a kind gift from Dr Erik Schweitzer
(UCLA [42]). Cells were cultured in DMEM containing
5% horse serum, 5% calf serum and 1% L-glutamine
(Fisher Scientific, Pittsburgh, PA), 1% penicillin/strep-
tomycin and 1% geneticin (Invitrogen, Grand Island,
NY) in a humidified atmosphere containing 9.5% CO2
at 37°C. Cells were cultured in collagen-coated T75s
and plated for experiments onto poly-D-lysine-coated
96-well plates (20,000 per well, no cells were plated in
the outermost wells; plates and flasks from BDBios-
ciences, San Jose CA). On the following day after plat-
ing, the cells were induced with 0.1 μM Tebufenozide,
a kind gift from Dr Erik Schweitzer (UCLA), or treated
with ethanol (vehicle) and also treated with curcumin
( S i g m aA l d r i c h ,S t .L o u i s ,M O ;5n M ,5 0n M ,5 0 0n M ,
5 μM, 10 μMo r2 0μM) or DMSO (Fisher Scientific;
vehicle for curcumin) using dilutions of 1:1000 to pre-
vent toxicity from the DMSO or ethanol. Four wells
were used for each treatment (8 for control-treated
induced cells), the positions of which were pseudoran-
domized between independent experiments (n = 4).
Cells were cultured for 48 or 72 h and then the med-
ium was removed, the cells were washed in warmed
PBS and then fixed in cold 4% PFA for 30 mins. The
cells were washed again and covered with fluorescent
mounting medium and stored in the dark for analysis.
For analysis of aggregates, photomicrographs, at 10×
magnification, were taken and were analyzed using
ImageJ. One photo, centered over the well, was taken
per well. The mean size of all aggregates per field of
view (FOV, i.e., 1 FOV per well) was calculated by
ImageJ. This mean size was then expressed as a pro-
portion of the mean aggregate size of all control-trea-
ted induced wells. These proportions were then used
for the final quantification and statistical comparisons,
such that each treatment group contained n = 4 repli-
cates, each from an independent experiment.
Mice, husbandry, treatment
All experiments were performed in accordance with the
US Public Health Service Guide for Care and Use of
Laboratory Animals and were approved by the Institu-
tional Animal Care and Use Committee at UCLA.
CAG140 mice were bred in house from heterozygous
(Het) KI × Het pairings (non-sibling pairs only). Resul-
tant WT and homozygous KI mice were used for
behavioral analyses. Het progeny were used to monitor
body weight only. Mice were N3 (B6) on a 129 Sv ×
C57BL/6 J background.
Breeding mice (5 males, 10 females per group) were
fed normal chow (NIH-31 number 7013, Harlan Teklad,
Indianapolis, IN) or the same chow containing 555 ppm
curcumin (Sigma Aldrich, St. Louis, MO) for at least 1
week prior to breeding and throughout breeding. This
regimen was chosen based on previously published pre-
clinical trials in mouse models of Alzheimer’sd i s e a s e
showing drug effects in brain, and measurable curcumin
in brain parenchyma following oral administration
[20,25,26]. Breeding pairs were checked daily for litters,
and the number of pups in each litter was noted at
birth and at weaning. In some cases, the number of
pups increased from the number at birth and this is due
to incomplete parturition at the time that the litter was
first counted. Two rounds of breeding were used to gen-
erate mice for the preclinical trial, and equal numbers of
litters were generated in both treatment groups (n = 18
per treatment group). Groups were matched for gender,
and group sizes were n = 30 - 32 for WTs, and n = 16-
17 for KIs. HET mice (n = 15-19) were used only to
monitor body weight and curcumin brain levels, and
were not used for any behavioral testing. Progeny were
genotyped and weaned by 21 days and curcumin or con-
trol chow was continuously fed to the mice until 4.5
months of age. Body weight was recorded weekly. Tail
samples were taken at the end of the experiment in
order to confirm genotyping and to measure CAG
repeat length. The mean CAG repeat length alleles,
measured by Laragen Inc., Culver City, CA, using an
ABI 3730 sequencer and Genemapper software, were
117 ± 1 (n = 50) in control diet-treated, and 113 ± 1.4
(n = 46) (mean ± sem) in curcumin-treated KI mice
(frequency distributions not significantly different, Chi
square independence: ns).
To control for effects of developmental exposure to
curcumin, an additional trial was conducted in 39 adult
WT C57Bl/6 J (B6) mice purchased from Jackson
laboratories (Bar Harbor, ME). Following 1 week habi-
tuation to housing, the mice were divided into weight-
and gender-matched control-fed groups (N = 10 males,
N = 10 females) and curcumin-fed groups (N = 10
males, N = 9 females). Mice were fed normal or curcu-
min chow, as above, from 2.7 months of age until 8
months. Prior to start of trial, mice were tested for
climbing, grip strength and body weight, and groups
were balanced using these data.
Food and water were available ad lib, and stocks of
chow were stored at 4°C. Mice were housed in a tem-
perature and humidity controlled room, on a reverse
light-dark cycle (11 am lights off, 11 pm lights on). For
food utilization for the trial in adult mice, chow was
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per day calculated.
Tissue sample preparation for HPLC
Measurements of curcumin in brain tissue were carried
out as described previously [20]. Briefly, fresh frozen
(WT, n = 2 control, n = 3 curcumin; mice were from
the behavior trial) or PBS-perfused and subsequently
f r e s hf r o z e n( H E T ,n=4c o n t r o l ,n=5c u r c u m i n ;
HETs were treated in parallel to mice in the behavioral
trial) hemispheres of brain from mice treated with con-
trol- or curcumin-containing food were weighed, then
finely powdered and homogenized in 10 vol of 1 M
ammonium acetate (pH 4.6). Mice were euthanized at
the end of the trial thus following approximately 5.5 m
of treatment, which includes gestation, weaning and up
to approximately 4.5 m of age. Homogenates were
extracted in 95% ethyl acetate/5% methanol and dried
under a continuous flow of N2. Dried extracts were
redissolved in acetonitrile/methanol/water/acetic acid
(41/23/36/1, all by volume), and injected onto a reverse
phase HPLC column (Supelco Ascentis Express C18,
150 × 2.1 mm) equilibrated in 10 mM ammonium acet-
ate and eluted (100 μl/min) with an increasing concen-
tration of acetonitrile/isopropanol. Samples were
detected at 262 nm, using tetramethoxycurcumin as an
internal standard. The effluent from the column was
passed directly to an Ionspray™ ion source connected
t oat r i p l eq u a d r u p o l em a s ss pectrometer (PerkinElmer
Life Sciences Sciex API III+). The retention times of
curcumin and internal standard were 28.24 and 30.27
min, respectively.
Neuropathological analysis
A subset of curcumin- and control-fed CAG140 KI mice
(n = 6 per group) were anesthetized and perfused with
4% paraformaldehyde and 0.5% glutaraldehyde, their
brains removed, post-fixed for 6-8 h in 4% paraformal-
dehyde, cryoprotected in 30% sucrose and frozen for
use. Sagittal cryosections at the level of 1.32 mm and
2.28 mm lateral of the midline [47] were used for analy-
sis. Tissue cryosections (35 μm) were stained with poly-
clonal EM48 (EM48; X-J Li, Emory University) as
described in [12]. Briefly, sections were washed in 0.01
M PBS and then endogenous peroxidases were inacti-
vated by incubating in 1% H2O2 and 0.5% Triton X-100
in PBS, for 20 min. Non-specific binding sites were then
blocked by incubating sections for 30 min at room tem-
perature in PBS containing 3% bovine serum albumin
(BSA) and 2% normal goat serum (NGS). The primary
antibody, EM48, was diluted (1:300) in PBS containing
3% BSA, 2% NGS, 0.08% sodium azide, and 0.2% Triton
X-100 and sections were incubated overnight at room
temperature. The following day the sections were
washed in PBS and then incubated in biotinylated goat
anti-rabbit antibody (1:200; Vector ABC Elite; Vector,
Burlingame, CA) for 2 h at room temperature, washed
and then reacted with avidin-biotin complex (Vector
ABC Elite) in PBS containing 0.2% Triton X-100 for 2
h. Immunoreactivity was visualized by incubation in
0.03% 3-3-diaminobenzidine tetrahydrochloride (Sigma,
St. Louis, MO) and 0.0006% H2O2 in 0.05 M Tris buffer,
pH 7.6. After rinses in Tris buffer, the sections were
dehydrated, defatted, and mounted with Eukitt (Cali-
brated Instruments, Hawthorne, NY). Control sections,
processed in parallel, were incubated in the absence of
t h ep r i m a r yo rs e c o n d a r ya n t ibodies. No staining was
noted in control sections (data not shown). Huntingtin-
stained nuclei and aggregates were analyzed with Stereo
Investigator 5.00 software (Microbrightfield, Colchester,
VT). Briefly, the contours of the striatum were drawn at
5× magnification. The software then laid down a sam-
pling grid of 200 × 200 μm, on which counting frames
of 20 × 20 μm were placed. Counting frames were
located on the top left corner of each sampling grid,
thus allowing for unbiased sampling, and these counting
frames were used for quantification of each type of
aggregate per section. Quantification was done at 100×
magnification, using a 1.4 NA lens and 1.4 NA oil con-
denser, with a DVC real-time digital camera. The mean
number of 1) stained nuclei, 2) nuclei containing micro-
aggregates, 3) nuclei containing inclusions and 4) neuro-
pil aggregates, per counting frame, was calculated per
striatal section, per mouse. These data were then used
to generate group means. Microaggregates [12,74] were
defined as numerous, small, nuclear puncta, similar to
those previously observed in other models of HD
[44-46].
Quantitative real time PCR analysis
A subset of curcumin- and vehicle-treated CAG140 WT
and KI mice (control-treated: WT n = 8, KI n = 7; cur-
cumin-treated: WT n = 8, KI n = 7) were quickly
decapitated and their brains frozen in powdered dry ice.
Total RNA was purified from one striata of fresh frozen
tissue using QiaGen RNeasy mini kit (protocol as
described by manufacturer, QIAGEN Sciences, Mary-
land, USA). During the RNA extraction procedure
DNAse 1 treatment was performed to remove contami-
nating genomic DNA (RNase-Free DNase Set, QIAGEN,
Hilden, Germany). The Invitrogen ThermoScript RT-
PCR System (Invitrogen, Carlsbad, CA, USA) was used
for cDNA synthesis with oligo dT primers. The cDNA
was then analyzed by quantitative real time PCR using a
Roche LightCycler 480 (UCLA Genotyping and Sequen-
cing Core). PCRs were performed using LightCycler Fas-
tStart DNA Master plus SYBR Green 1 kit (Roche
Diagnostics, Mannheim, Germany). Each assay included:
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trol cDNA (mouse EST clone of appropriate fragment
of the gene of interest (Invitrogen, CA), 2) sample
cDNA, 3) no template control. All samples were run in
triplicates. The PCR cycling parameters were: 95°C for 5
min (1 cyc); 95°C for 10 sec, 65°C for 10 sec, 72°C for
10 sec (40 cyc). A dissociation protocol was established
at the end of each run to verify the presence of a single
product. The relative expression of genes of interest was
calculated from Ct values using the Pfaffl method [54].
PCR efficiencies of each primer pair were calculated
from standard curve analysis and incorporated into rela-
tive quantification calculations. The endogenous control
was HPRT, hypoxanthine phosphoribosyltransferase,
which was reported to be unchanged in mouse and
human microarray studies [50,75] and has been used in
other previous RT-PCR studies examining transcript
changes in HD [50-52]. Designed primers yielded a pro-
duct of about 200 bp for each gene (Table 5).
General health monitoring and behavioral testing
All analysis was carried out blinded to genotype and
treatment. Mice were habituated to the testing rooms
for 15-20 mins prior to all testing. Body weight was
monitored in both trials and the amount of chow uti-
lized was also quantified in the adult trial. Open field,
pole task, and rotarod testing all took place in the dark
phase, while climbing activity was recorded during the
light phase [11,12]. For the life-time curcumin trial,
CAG140 KI and WT mice were tested at 1 m of age in
the open field, 1.5 months in the climbing test, and at 4
months in the pole test and the rotarod [11,12]. This
schedule was chosen to avoid excessive repeated testing
that could influence the progression of the disease. For
the trial in adult WT mice, mice were tested 4.5 and 8
months of age in the climbing test and the rotarod, and
at 8 months of age in the open field (for 15 mins daily
over a period of 4 d). In addition, WT mice in the adult
trial were also tested for grip strength, a measurement
of forelimb muscle strength as described previously [76]
at 3.5, 4.5 and 8 months of age. Finally, in this trial, WT
m i c ew e r et e s t e du s i n gt h eP o r s o l ts w i mt a s ka t8
m o n t h s[ 7 7 ] .T h e yw e r ea l s ot e s t e du s i n gt h et a i ls u s -
pension task [78] however, several mice “escaped” the
tail suspension task by climbing up their tail ([79] n = 2
male control, n = 5 female control, n = 1 male curcu-
min, n = 3 female curcumin), thus forced swim test data
only were used.
For rearing activity mice were placed individually in
the center of the open field (Truscan, Coulbourn Instru-
ments, Allentown, PA) and video recorded for later ana-
lysis. Mice were tested in 2nd through 4th hours of the
dark cycle, using a red light (25 W) for illumination. For
climbing, mice were placed in a wire cylinder (3 ¾″
height × 4″ diameter) for 5 mins and their behavior
recorded for later video analysis, as described previously
[11]. For the pole task mice were placed head facing
upwards on a vertical pole and trained to turn around
and descend to the bottom of the pole, as described pre-
viously [11]. For rotarod performance mice were trained
to walk on an accelerating rotating axle (Ugo Basile,
Varese, Italy), as previously described with slight modifi-
cations [11]. Briefly, mice were given 3 trials/day over 4
days (5-40 rpm over 10 mins, with approximately 30
mins between successive trials) and the latency to fall
was measured. For training the axle of the rotarod was
covered with smooth rubber (smooth axle). On the 5th
day mice received 1 trial at each of 10, 20 and 30 rpm
(smooth axle) and on the final day mice received 1 trial
at each of 20, 24, 30 and 36 rpm using a grooved axle.
Testing was carried out approximately half way through
the dark phase, under a red light (25 W). Any mice that
clung to the axle for 3 successive rotations were
removed and the time of removal recorded and used as
the latency. The proportion of mice that cling is very
small, thus we did not analyze these animals separately
[11]. For the Porsolt swim task (adult trial only), mice
were placed in 12 cm of water (temperature: 26°C) in a
large Plexiglas beaker for 6 mins and their behavior was
videotaped for analysis. Latency to become immobile
and duration of immobility were quantified.
Statistical analysis
GBstat (V8.0) and SAS (V 9.1) were used for statistical
analyses. Comparisons of in vitro aggregate size propor-
tions were completed using Kruskal-Wallis ANOVAs
followed by Mann Whitney U tests. For in vivo data,
outliers were detected using Grubbs test and removed
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nostained nuclei and aggregates) were analyzed with
completely randomized ANOVAs followed by Fisher’s
LSD for post hoc analysis. For qRT-PCR results, data
were analyzed with completely randomized ANOVAs
followed by Bonferroni t tests, corrected for 4 compari-
sons (control-fed WT V control-fed KI; control-fed WT
V curcumin-fed WT; control-fed WT V curcumin-fed
KI; control-fed KI V curcumin-fed KI). Correlations of
mRNA data were carried out in GraphPad prism V4.
Comparisons of husbandry data were made with Stu-
dent’s t tests or repeated measures ANOVA followed by
Fisher’s LSD post hoc tests. Body weights were analyzed
using mixed generalized linear model ANOVAs in SAS
using Bonferroni’s adjusted Student’s t-tests for post hoc
analysis. Behavioral data and food intake were analyzed
using one, two or three factor ANOVAs followed by
Fisher’s LSD for post hoc analysis. Significance was
defined as a = 0.05 for all analyses.
Abbreviations
HD: Huntington’s disease; WT: Wildtype; KI: Homozygous knock in; Het:
Heterozygous knock in; ns: Non-significant
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